NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Delfi Diagnostics

Delfi Diagnostics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://delfidiagnostics.com/

Last Round

VC Round

Dec 18, 2025

Total Funding Raised

$330.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Delfi Diagnostics is a biotechnology company that develops high-performance, accessible blood-based tests for the early detection of cancer using machine learning to analyze cell-free DNA fragmentation patterns.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

liquid biopsyearly cancer detectionfragmentome analysiscell-free DNAcfDNAcancer screeningprecision oncologylaboratory-developed testLDTblood-based diagnosticscancer blood testlung cancer screeningdiagnostic AIclinical diagnosticsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Delfi Diagnostics Comps

Public and private peers based on sector, stage, and business model.

Delfi Diagnostics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Delfi Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundDec 18, 2025
Corporate FundingJun 4, 2024
Series BJul 18, 2022
Series AJan 12, 2021
SeedAug 1, 2019

Key People

Founding team and executive leadership

Susan Tousi

CEO

Executive Team

Delfi Diagnostics Investors

Notable investors and investment history

Delfi Diagnostics investors
InvestorRounds
PTX CapitalSeries B
Brown AdvisorySeries B
Bollinger Investment GroupSeries A
TD SecuritiesSeries B, Series A
Blue Owl CapitalSeries B, Series A
Osage University PartnersSeries B
OrbiMedSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Five poster presentations at AACR 2026 Annual Meeting.

  • Apr 6, 2026

    Showcasing advances to whole-genome cfDNA platform at AACR 2026.

Delfi Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Delfi Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Delfi Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range159
Year Founded2019
Last FundingDec 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.